Expert Profile
Sumon ***** , MD, is Clinical Professor of Diabetes and Endocrinology at Penn State College of Medicine. He has interest in strong relationships with patients and patient care as well as teaching medical residents and students. Dr. ***** has focus on diabetes management, insulins, inhaled insulins, intranasal insulins, DPP-4 inhibitors in development including saxagliptin, vildagliptin, alogliptin, and current sitagliptin as well as, GLP-1 agonists including liraglutide and BYETTA LAR, injection devices, viaject insulins, insulin delivery technologies, up and coming trials at ADA conferences, clinical trial development, marketing analysis of DM market, shift in market share, metabolic syndrome. Insulin sensitizers and beta cell preservation are also interests of his. Dr. ***** is knowledgeable on the efficacy, safety, and comparators in market to risk/benefit and placement in diabetes algorithm treatments in understanding the marketplace.
Endocrinology, Diabetes and *****, 2004-Present
Lehigh Valley Hospital, Allentown, PA
Clinical Assistant Professor of Medicine, Division of Endocrinology,
Penn State Medical School
-Lehigh Valley Hospital is One of Top Rated in Diabetes and Endocrinology in
U.S. News & World Report 2006 and listed in “Americas Best Hospitals” 15 consecutive
years
-Lehigh Valley Hospital is FORTUNE 100 Best Companies to work for 2007
Fellowship Robert Wood Johnson University Hospital, New Brunswick, NJ *****
Endocrinology, Diabetes, and *****
Residency Thomas Jefferson University Hospital, Philadelphia, PA *****
Internal Medicine
M.D. UMDNJ-New Jersey Medical School, Newark, NJ *****
The Endocrine Society-attend annual meetings
-FACE- AACE, Fellow of American Association of Clinical Endocrinologists- ADA, American Diabetes Association- attend annual meetings
GLG Councils
Stepwise treatment algorithm with rapid acting anologues once basal insulin is optimized
CSII(continuous subcutaneous insulin infusion) as insulin pump therapy-favorable alternative to MDI sq
CGMS in concert with CSII-practical advantages in insulin therapies
Utility of CGMS in identifying postprandial hyperglycemia and nocturnal hypoglycemia-use in idealizing carb count ratios
Advantages to insulin glulisine as a rapid acting alternative-flexibility, weight advantages, step wise therapy to basal insulin, and absorption advantages across BMI groups
Role of Insulin Management with the Advent of Basal Insulin Glargine
Understanding of Basal-Bolus Therapy in the utilization of Insulin and MDI
Overcoming physician’s “insulin resistance”
Metabolic Syndrome and improving LPL Dysfunction with the utilization of basal insulin
Resolution of Glucose Toxicity with insulin management
Life threatening Thyrotoxicosis Induced by Combination Therapy with Peg-Interferon and
Ribavarin in Chronic Hepatitis C, Endocrine Practice, March/April 2005
Reviewer for National Board of Medical Examiners, Endocrinology, Diabetes, and *****-ABIM